dPEG - World ADC

www.quantabiodesign.com
Tailored Single Molecule PEGs (dPEG®’s) in
Modifying the Performance of Biologics
Alex Pokora
Chief Operating Officer
Quanta BioDesign, Ltd.
 Technology Update
 Manufacturing Update
 New Products
What are unique properties of
dPEG® technology?
• Exact mass of a single PEG with all size options
– Chemistry options with perfect control of distance and size
• Offers much more complex and enabling design
Effect of dPEG® MW
versus
Binding Efficiency
Fab’-Control
Fab’-4kD neutral
Fab’-4kD acid
Fab’-8kD neutral
Fab’-15kD neutral
Competition ELISA
Fab’-control
Absorbance at 450nm
Fab’-4kD acid
Fab’-4kD neutral
Fab’-8kD neutral
Fab’-15kD neutral
Log of Conjugate Concentration
Fab’-Conjugate MW Determinations
Fab’
Fab’-control
Fab’-3K
Fab’-4kD acid
Fab’-8kD neutral
Fab’-15kD
neutral
Estimated
Weight
48,000
48,125
52,299
52,473
56,323
63,592
MW by MALDI
MS
48,330
48,520
52,533
52,884
56,688
63,819
43,176
55,302
61,491
81,595
116,206
-0.1x
0.62x
1.9x
3.0x
3.4x
MW by SEC
Apparent
Mass
Increase
24 hour COMPARISON
m-CC49-Fab’-S-MAL-dPEG®12Tris(-dPEG®24 acid)3
m-CC49-Fab’-S-NEM
Bromoacetamido dPEG®x Linkers
PN10285; Maleimido-dPEG®12-acid
A
PN11209; Bromoacetamido-dPEG®12-acid
PN10319; m-dPEG®24-MAL
B
PN11214; m-dPEG®24-Bromoacetamide
Bromoacetamido dPEG®x Linkers
C
PN11204; Bromoacetamido-dPEG®11-azide
MAL-dPEG®11-azide
MAL-dPEG®x-azide is not a stable compound. It can be
made and used immediately, but often that is impractical,
and yields are not very good. The BromoacetamidodPEG®11-azide is a stable compound if stored as
recommended.
Not shown, but also tested, were the maleimide and
bromoacetamide derivatives of an approximately 5 KDa
branched dPEG® derivative.
D
Maleimide vs Bromoacetamide
A
B
Terms and Conditions
Quanta BioDesign, Ltd. owns self-developed technologies, materials and information, as well as accompanying patents, patent applications, knowhow and practical knowledge for the production of discrete polyethylene glycols, dPEG®s, and related products.
The following are standard terms of trade and are an integral part of all quotations and sales of Quanta BioDesign, Ltd. to customers, buyers and
business enterprises:
1. By placing a Purchase Order, the customer accepts the standard Terms and Conditions of Sale of Quanta BioDesign, Ltd. as binding.
2. Payment terms of sale are net 30 days of date of invoice, unless otherwise stated. Credit Cards may not be used on past due invoices.
3. Products sold are solely for use by qualified individuals who are experts in their fields for laboratory use only and are not intended to be used
for any other purposes, including but not limited to, in vitro diagnostic purposes, in foods, drugs, medical devices, cosmetics or commercial use.
Customer represents and warrants to Quanta BioDesign, Ltd. that Buyer will properly test, manufacture, use and market any products
purchased from or materials produced from products made or purchased from Quanta BioDesign, Ltd. in strict compliance with all applicable
laws and regulations.
4. Nothing in terms of trade or quotation of orders by Quanta BioDesign, Ltd. may be interpreted such that they would result in the assignment of
rights of manufacture by Quanta BioDesign, Ltd. technology to the customer.
5. A separate licensing agreement/supply agreement between Quanta BioDesign, Ltd. and its customer will be necessary for the use of Quanta
BioDesign, Ltd. products in applications beyond laboratory use. Customers are responsible to informing Quanta BioDesign when products are
being used beyond lab use.
6. All goods must be inspected upon arrival and may not be returned for credit except with Quanta BioDesign, Ltd.’s permission. Due to the cost
of re-qualifying product, there is a charge of $250 for each previously un-opened vial/bottle that is returned. No previously opened product will
be accepted. Please note there are no returns on bulk quantity purchases.
7. Quanta BioDesign, Ltd.’s products are subject to US export laws, treaties, rules international agreements and regulations. All customers
purchasing Quanta BioDesign, Ltd.’s products assume the responsibility of abiding by US export laws, treaties, rules international agreements
and regulations along with applicable foreign laws.
Please Note: International customers are responsible for any international customs, duties or taxes on merchandise delivered to addresses outside the
United States. These amount are not included in the shipping charges shown on invoices and will be billed to the customer separately by the chosen
carrier, if applicable.
®
dPEG
CC49 Diabody Drug Conjugates
against TAG-72 for Cancer Therapy
Megan Minnix, John Shively, David Colcher, Paul Davis1 and Peter Hudson2
1-Quanta BioDesign; 2-Avipep, Inc.
•
Chemistry
– Paul D. Davis & QBD Chemistry Staff
•
Conjugation & Characterization
– Melissa Vermillion, Robert Woodman; Quanta BioDesign, Ltd.
•
Antibody Production
– David Colcher, Paul Yazuki; City of Hope
•
Mass Spec
– Nan Kleinholz OSU CCIC